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ABSTRACT 
Objective. We evaluated the laboratory 
and radiological data on liver and in-
vestigate liver fibrosis induced by hepat-
ic manifestation of antineutrophil cyto-
plasmic antibody-associated vasculitis 
(AAV) using the aspartate aminotrans-
ferase to platelet ratio index (APRI) and 
an index of fibrosis (FIB-4) in 136 im-
munosuppressive drug-naïve patients.
Methods. We retrospectively reviewed 
the medical records of 136 patients with 
AAV without chronic liver diseases or 
autoimmune diseases. We collected the 
laboratory and imaging results. We as-
sessed liver fibrosis by APRI and FIB-4. 
The critical cut-offs of APRI and FIB-4 
for predicting liver fibrosis are 0.5 and 
1.45. The optimal cut-off of five fac-
tor score (FFS) at diagnosis for FIB-4 
≥1.45 was extrapolated by the area un-
der the receiver operator characteristic 
curve. 
Results. The mean age at diagnosis 
was 54.6 years and 32.4% of patients 
were male (69 MPA, 38 GPA and 29 
EGPA). The percentage of patients hav-
ing the normal results of liver function 
tests was ranging from 86.0% to 95.6%. 
There were no patients who exhibited 
the significantly abnormal findings on 
imaging studies. Nonetheless, twenty-
nine patients with AAV (21.3%) exhib-
ited subclinical but significant liver 
fibrosis at diagnosis based on FIB-4. 
Patients with FFS ≥1 had a significant-
ly higher risk of having subclinical but 
significant liver fibrosis (FIB-4 ≥1.45) 
than those with FFS <1 (RR 12.486). 
Conclusion. AAV may increase the re-
sults of liver function tests and it may 
provoke subclinical but significant liver 
fibrosis at diagnosis. Furthermore, liv-
er fibrosis should be considered in AAV 
patients having FFS ≥1. 
Introduction
Antineutrophil cytoplasmic antibody 
(ANCA)-associated vasculitis (AAV) 
is a group of systemic vasculitis in-
volving small vessels from capillaries 
to intraparenchymal arterioles and ven-
ules. AAV is composed of three vari-
ants including microscopic polyangii-
tis (MPA), granulomatosis with poly-
angiitis (GPA) and eosinophilic granu-
lomatosis with polyangiitis (EGPA) 
(1). Despite the pivotal role of ANCA 
to initiate pathogenic autoimmunity, 
the clinical utility of serially measuring 
ANCA titres is still controversial (2). 
AAV usually affects almost all the ma-
jor organs leading to various symptoms 
and signs as described in Birmingham 
vasculitis activity score (BVAS) and 
BVAS for GPA (3, 4). However, hepat-
ic manifestation of AAV has not been 
emphasised to date unlike other major 
organs, and furthermore hepatic mani-
festation is not included in BVAS (3). 
So far, only a few studies have reported 
the abnormal results of liver function 
tests. A previous study reported that 
liver enzyme levels were elevated in 
2~25% of Italian patients with AAV 
at diagnosis (5), and another recent 
study demonstrated that 49% of Ger-
man patients with AAV had abnormal 
results of liver function tests and GPA 
patients exhibited liver involvement of 
AAV more frequently than other vari-
ants during the active status (6). Nev-
ertheless, in the real clinical settings, 
cases exhibiting the serious abnormal 
results of liver function tests and imag-
ing studies as the initial manifestation 
of AAV are not common. 
On the other hands, given that liver is 
one of the organs with plenty of cap-
illaries, like lungs and kidneys, AAV 
may occur in liver more frequently 
than is expected. However, hepatic 
manifestation of AAV might have been 
underestimated due to less significant 
symptoms than those in other major or-
gans, or ignored by concerns on inva-
sive liver biopsy (7, 8). Theoretically, 
it can be assumed that autoimmune-
related inflammation of AAV can in-
duce the hepatocellular damages, the 
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expansion of myofibroblast and the 
activation of stellate cells (9). A series 
of these responses, in turn, can enhance 
the potential of liver fibrosis in patients 
with AAV similar to autoimmune hepa-
titis and primary biliary cirrhosis (10). 
Meanwhile, authors recently demon-
strated subclinical but significant liver 
fibrosis in up to 15% of patients with 
rheumatic diseases, in whom the re-
sults of liver function tests and imaging 
studies were all normal (11-13). There-
fore, it must be valuable to first evalu-
ate liver fibrosis in AAV patients. But, 
due to the limitation of a retrospective 
study, liver biopsy or transient elas-
tography cannot be performed in AAV 
patients, to whom immunosuppressive 
drugs were not administered. Instead, 
liver fibrosis can be estimated using 
non-invasive evaluation-equations cal-
culated by the results of liver function 
tests at diagnosis of AAV, which may 
compensate for that limitation. 
Among various indices for predicting 
liver fibrosis, the aspartate aminotrans-
ferase to platelet ratio index (APRI) 
and an index of fibrosis (FIB-4) are 
widely used (14). First, APRI has been 
introduced as an available method to 
assess liver fibrosis in chronic hepatitis 
C and validated in non-alcoholic fatty 
liver disease and autoimmune hepati-
tis. APRI is calculated using AST, the 
upper limit of AST and platelet count. 
Because APRI <0.5 may rule out sig-
nificant fibrosis and cirrhosis, the 
critical cut-off of APRI for predicting 
moderate fibrosis (S2) to cirrhosis (S4) 
is set as 0.5 (15). Second, an index of 
fibrosis (FIB-4) has been also proposed 
to assess liver fibrosis in HCV-monoin-
fected patients. FIB-4 is calculated us-
ing age, ALT, AST and platelet count. 
Because FIB-4 <1.45 had a negative 
predictive value of 94.7% to exclude 
severe fibrosis with sensitivity of 0.74, 
the critical cut-off of FIB-4 for predict-
ing significant liver fibrosis (S2 to S4) 
is set as 1.45 (16). So far, to our best 
knowledge, there was no report regard-
ing liver fibrosis assessed by APRI and 
FIB-4 in AAV patients. Hence, in this 
study, we evaluated the results of liver 
function tests and the findings of imag-
ing studies, and investigate liver fibro-
sis induced by hepatic manifestation of 
AAV using APRI and FIB-4 in 136 im-




We retrospectively reviewed the medi-
cal records of 160 patients with AAV 
based on the inclusion criteria as fol-
lows: i) patients who were first classi-
fied as AAV from October 2000 to Sep-
tember 2017 at Division of Rheumatol-
ogy, Department of Internal Medicine, 
Yonsei University College of Medicine, 
Severance hospital; ii) patients who 
fulfilled the American College of Rheu-
matology 1990 criteria for the clas-
sification of GPA and EGPA and then 
reclassified by the algorithm suggested 
by the European Medicines Agency in 
2007, in which authors added the modi-
fied contents of the Chapel Hill Con-
sensus Conferences (CHCC) Nomen-
clature of Vasculitis proposed in 2012 
(1, 17-19); iii) patients who had well-
documented medical records to assess 
clinical manifestations at diagnosis and 
calculate vasculitis activity score rep-
resented by BVAS or BVAS for GPA 
and prognostic factors identified by five 
factor score (FFS (2009)) at diagno-
sis (3, 4, 20); iv) patients who had the 
results of perinuclear (P)-ANCA and 
cytoplasmic (C)-ANCA or myeloper-
oxidase (MPO)-ANCA and proteinase 
3 (PR3)-ANCA at diagnosis (21); v) 
patients who had no history of chronic 
liver diseases, such as viral hepatitis or 
alcoholic liver diseases identified in the 
10th revised International Classification 
Diseases (ICD-10); vi) patients who 
had never received both immunosup-
pressive drugs for AAV or drugs for 
chronic liver diseases under the Ko-
rean Drug Utilisation Review (DUR) 
system; vii) patients who had no his-
tory of autoimmune diseases including 
autoimmune hepatitis or administra-
tion of immunosuppressive drugs for 
them, which can affect liver function 
and structure (22); viii) patients who 
did not suffer from excessive alcohol 
intake or serious obesity (body mass in-
dex >35) (23); ix) patients who had the 
results of liver function tests at diagno-
sis including variables of equations to 
estimate liver fibrosis; x) patients who 
might have the results of imaging stud-
ies on liver including ultrasonography 
or computed tomography at diagnosis 
(not obligatory).  
Among 160 patients with AAV, nine 
patients were excluded due to HB-
sAg positive (n=4), anti-HCV positive 
(n=1), alcoholic hepatitis (n=3) and 
non-alcoholic steatohepatitis (n=1). 
Of these 151 patients with AAV with-
out chronic liver diseases, 15 patients 
were further excluded due to concomi-
tant autoimmune diseases including 
rheumatoid arthritis (n=6), Sjogen syn-
drome (n=4), systemic sclerosis (n=2), 
ankylosing spondylitis (n=2) and 
systemic lupus erythematosus (n=1). 
Finally, 136 patients with AAV were 
included in this study and selected for 
statistical analysis (Fig. 1). This study 
was approved by the institutional Re-
view Board (IRB) of Severance Hos-
pital (4-2017-0673), and the patient’s 
written informed consent was waived 
by the approving IRB, as this was a ret-
rospective study.
Clinical and laboratory data 
and radiological evaluation
We obtained age at diagnosis and gender 
as demographic data. We searched the 
initial ANCAs: P-ANCA and C-ANCA 
were evaluated by immunofluorescence 
assay. MPO-ANCA and PR3-ANCA 
had been measured by Enzyme-Linked 
immunosorbent assay (ELISA) kit for 
anti-PR3 and anti-MPO (Inova Diag-
nostics, San Diego, USA) before 2013, 
and by the novel anchor coated highly 
sensitive (hs) Phadia ELiA (Thermo 
Fisher Scientific/Phadia, Freiburg, Ger-
many) using human native antigens, 
performed on a Phadia250 analyser af-
ter 2013. Based on the medical records, 
we refilled the form of vasculitis activ-
ity score for AAV and calculated BVAS 
(representing both BVAS and BVAS for 
GPA) as well as FFS (2009) at diagno-
sis (3, 4, 20). 
We collected laboratory results at diag-
nosis including erythrocyte sedimen-
tation rate (ESR), C-reactive protein 
(CRP), while blood cell count, hae-
moglobin, platelet count, prothrom-
bin time, fasting glucose, blood urea 
nitrogen, creatinine, serum albumin, 
alkaline phosphatase (ALP), aspartate 
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transaminase (AST), alanine transami-
nase (ALT), total bilirubin and total 
cholesterol. In addition, the normal 
ranges of liver function tests were set 
as the follows: platelet ≥150,000/mm3, 
prothrombin time ≤1.16 international 
normalised ratio (INR), alkaline phos-
phatase (ALP) ≤115 IU/L, aspartate 
aminotransferase (AST) ≤40 IU/L, ala-
nine aminotransferase (ALT) ≤40 IU/L, 
total bilirubin ≤1.2 mg/dL. 
We counted the number of patients 
having the results of liver function tests 
within normal ranges. 
Ninety-seven patients with AAV un-
derwent ultrasonography and com-
puted tomography scan at diagnosis 
of AAV with reasons as follows: i) for 
abnormal results of liver function tests; 
ii) for abdominal manifestations other 
than hepatic manifestations and iii) for 
baseline study (Fig. 1). We reviewed 
the radiological findings of imaging 
studies and counted the number of cas-
es with abnormal findings. 
Equations to predict 
significant liver fibrosis 
To predict subclinical but significant 
liver fibrosis in AAV patients, we used 
two widely used equations as below: i) 
APRI = AST level (IU/L) / AST upper 
limit of normal range (IU/L) / platelet 
count (109/L); ii) Fibrosis-4 (FIB-4) = 
age (years) x AST level (IU/L) / platelet 
count (109/L) / √ALT (IU/L). The criti-
cal cut-offs of APRI and FIB-4 to pre-
dict liver fibrosis ≥S2 are 0.5 and 1.45 
(24).
Statistical analyses
All statistical analyses were conducted 
using SPSS software (v. 23 for win-
dows; IBM Corp., Armonk, NY, USA). 
Continuous variables were expressed as 
mean ± standard deviation, and categor-
ical variables were expressed as num-
ber and the percentage. Differences in 
the results of liver function tests among 
three AAV variants were investigated by 
the ANOVA test. Significant differences 
in BVAS and FFS at diagnosis between 
the two groups according to the cut-offs 
of APRI or FIB-4 were evaluated by the 
Mann-Whitney test. The optimal cut-off 
of FFS for predicting FIB-4 ≥1.45 was 
extrapolated by calculating the area un-
der the receiver operator characteristic 
curve (AUROC) and selecting one with 
the maximised sum of sensitivity and 
specificity. In addition, the relative risk 
(RR) was analysed using contingency 
tables with the chi square test. p-values 




of 136 patients with AAV 
The baseline characteristics were de-
scribed in Table I. The mean age at di-
agnosis was 54.6 years and 44 patients 
(32.4%) were male. Of 136 patients 
with AAV, 69 patients were classified 
as MPA, 38 as GPA and 29 as EGPA. 
Eighty-two patients (60.3%) had MPO-
ANCA (or P-ANCA) and 24 (17.6%) 
had PR3-ANCA (or C-ANCA). Five 
patients (3.7%) had both MPO-ANCA 
(or P-ANCA) and PR3-ANcA (or C-
ANCA), and 33 (24.3%) had no ANCA. 
The mean BVAS at diagnosis was 12.3 
and the mean FFS (2009) at diagnosis 
was 1.2. In terms of the results of liver 
function tests at diagnosis, the mean 
platelet count (334, 700.0/mm3), pro-
thrombin time (INR) (1.0), ALT (89.5 
IU/L), AST (22.9 IU/L), ALT (22.7 
IU/L) and total bilirubin (0.6 mg/dL) 
were all in the normal ranges. 
Radiological features of liver 
in 97 patients with AAV
All patients with the abnormal results 
of liver function tests underwent im-
aging studies. There were no patients 
who exhibited serious chronic liver 
diseases on imaging studies. Seventy-
eight of 97 patients (80.4%) exhibited 
normal features of liver structures. 
Nine patients (9.3%) exhibited fatty 
liver, 5 patients exhibited hepatic cysts 
and 4 patients exhibited haemangioma. 
Liver abscess was incidentally found in 
one patient who was admitted for high 
fever and abdominal pain at the same 
time of diagnosis of AAV. 
Subclinical but significant 
liver fibrosis 
Based on the results of liver function 
tests and imaging studies, we found 
that the functional abnormalities and 
structural damages of liver were not 
apparent at diagnosis of AAV. How-
ever, because we did not perform inva-
sive liver biopsy or non-invasive liver 
stiffness measurement using transient 
elastography (Fibroscan®) in patients 
at diagnosis of AAV, we cannot lead 
to definitive conclusion that hepatic 
manifestation including liver fibrosis 
may be rare at the first visit. Instead, 
we estimated liver fibrosis by APRI 
and FIB-4. In terms of APRI, the criti-
cal cut-off for significantly liver fibro-
sis (S2-S4) is currently recommended 
as 0.5 (sensitivity 0.81 and specificity 
0.55). When we divided 136 patients 
with AAV into the two groups accord-
ing to the critical cut-off of APRI, only 
three of 136 patients (2.2%) exhibited 
APRI ≥0.5 (Fig. 2). In terms of FIB-4, 
Fig. 1. Selection of the study population. ANCA: antineutrophil cytoplasmic antibody; HBsAg: hepa-
titis B viral surface antigen; HCV: hepatitis C virus.
S-29Clinical and Experimental Rheumatology 2019
Subclinical liver fibrosis in AAV / S.-W. Lee et al.
the critical cut-off for significant liver 
fibrosis (S2-S4) is currently recom-
mended as 1.45 (sensitivity 0.64 and 
specificity 0.68). When we divided 136 
patients with AAV into the two groups 
based on the critical cut-off of FIB-4, 
twenty-nine of 136 patients (21.3%) 
exhibited FIB-4 ≥1.45 (Fig. 2). In addi-
tion, we compared the levels APRI and 
FIB-4 among MPO-ANCA (or P-AN-
CA), PR3-ANCA (or C-ANCA), both 
ANCAs and ANCA negative by One-
Way-Anova analysis. We found no 
statistically significant differences in 
APRI (p=0.385) and FIB-4 (p=0.075) 
according to ANCA subgroups. 
The association of BVAS or FFS 
with subclinical but significant liver 
fibrosis at diagnosis
We do not routinely calculate FIB-4 or 
perform transient elastography in AAV 
patients at diagnosis, unless they do 
not exhibit the significantly abnormal 
results of liver function tests. Mean-
while, we do routinely assess BVAS 
and FFS at diagnosis of AAV. Thus, if 
we find the optimal cut-off of BVAS or 
FFS for APRI ≥0.5 or FIB-4 ≥1.45 at 
diagnosis, we could recommend diag-
nostic tests for liver fibrosis to patients 
having more than the cut-off. 
We compared both BVAS and FFS at 
diagnosis between patients with APRI 
≥0.5 and those with APRI <0.5, but 
there were no significant differences 
between the two groups (13.7 vs. 12.2 
for BVAS, p=0.752 and 1.3 vs. 1.2 for 
FFS, p=0.861) (Fig. 2). We also com-
pared both BVAS and FFS at diagno-
sis between patients with FIB-4 ≥1.45 
and those with FIB-4 <1.45. The mean 
BVAS at diagnosis did not differ be-
tween the two groups (13.6 vs. 11.9, 
p=0.313). However, patients with FIB-4 
≥1.45 had the significantly higher mean 
FFS at diagnosis than those with FIB-4 
<1.45 (1.7 vs. 1.1, p=0.002) (Fig. 2). 
The optimal cut-off of FFS in 
predicting FIB-4 ≥1.45
Since the mean FFS at diagnosis was 
different between patients with FIB-4 
≥1.45 and those with FIB-4 <1.45, we 
calculated the optimal cut-off of FFS 
at diagnosis in predicting a potential of 
subclinical but significant liver fibrosis 
≥S2 based on AUROC analysis. We 
found that 1 of FFS at diagnosis was 
a strong predictor of FIB-4 ≥1.45 (area 
0.667, 95% confidence interval 0.566, 
0.769, sensitivity 0.97, specificity 
0.31). When we classified 136 patients 
with AAV into the two groups based on 
the calculated cut-off of FFS at diag-
nosis, thirty-four patients (25.0%) were 
partitioned into the group with FFS at 
diagnosis ≥1. FIB-4 ≥1.45 was identi-
fied more frequently in these patients 
than in those with FFS <1 (27.5% vs. 
2.9%, p=0.003). Furthermore, patients 
with FFS ≥1 had a significantly higher 
risk of having subclinical but signifi-
cant liver fibrosis according to FIB-
4 ≥1.45 than those with FFS <1 (RR 
12.486, 95% CI 1.629, 95.685) (Fig. 3).
Discussion
In this study, we evaluated hepatic 
manifestation of AAV using the results 
of liver function tests and the findings 
of imaging studies. Also we investi-
gated liver fibrosis by APRI and FIB-4 
Table I. Baseline characteristics of 136 patients with AAV.
Variables Values
Demographic data at diagnosis  
    Age (year old)  54.6 ± 15.8
    Male gender (n, (%)) 44 (32.4)
Variants of AAV 
    MPA 69 (50.7)
    GPA 38 (27.9)
    EGPA 29 (21.3)
ANCA at diagnosis (n, (%))  
    MPO-ANCA (or P-ANCA) 82 (60.3)
    PR3-ANCA (or C-ANCA) 24 (17.6)
    MPO-ANCA (or P-ANCA) and PR3-ANCA (or C-ANCA) 5 (3.7) 
    ANCA negative 33 (24.3)
Vasculitis activity and prognostic factors at diagnosis  
    BVAS or BVAS for GPA 12.3 ± 7.7
    FFS (2009) 1.2 ± 1.0
Acute reactants at diagnosis  
    Erythrocyte sedimentation rate (mm/hr) 62.6 ± 37.2 
    C-reactive protein (mg/L) 47.4 ± 58.4
Laboratory results at diagnosis   
    White blood cell count (/mm3) 10,394.4 ± 5,077.9
    Haemoglobin (g/dL) 11.1 ± 2.3
    Platelet count (x1,000/mm3) 334.7 ± 152.1
    Prothrombin time (INR)  1.0 ± 0.2
    Fasting glucose (mg/dL) 119.2 ± 46.9
    Blood urea nitrogen (mg/dL) 25.7 ± 24.6
    Creatinine (mg/dL) 1.9 ± 2.1
    Total protein (g/dL) 6.7 ± 0.9
    Serum albumin (g/dL) 3.6 ± 0.8
    Alkaline phosphatase (IU/L) 89.5 ± 78.5
    Aspartate transaminase (IU/L) 22.9 ± 16.7
    Alanine transaminase (IU/L) 22.7 ± 29.9
    Total bilirubin (mg/dL) 0.6 ± 0.3
    Total cholesterol (mg/dL) 167.9 ± 4.0
Proportion of patients with normal results of liver function tests (n, (%)) 
    Platelet count ≥150,0000/mm3 130 (95.6)
    Prothrombin time (INR) ≤1.16  117 (86.0)
    Alkaline phosphatase (IU/L) ≤115 IU/L 117 (86.0)
    Aspartate transaminase (IU/L) ≤40 IU/L 126 (92.6)
    Alanine transaminase (IU/L) ≤40 IU/L 123 (90.4)
    Total bilirubin (mg/dL) ≤1.2 mg/dL 130 (95.6)
Values are expressed as mean and standard deviation or n (%).
AAV: antineutrophil associated vasculitis; MPA: microscopic polyangiitis; GPA: granulomatosis with 
polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; MPO: myeloperoxidase; ANCA: 
antineutrophil cytoplasmic antibody; P-ANCA: perinuclear ANCA; PR3: proteinase 3; C-ANCA: cy-
toplasmic ANCA; BVAS: Birmingham vasculitis activity score; FFS: five factor score; INR: interna-
tional normalised ratio.
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in 136 patients with AAV at diagnosis. 
First, in 136 patients with AAV without 
chronic liver disease and autoimmune 
diseases, the mean results of liver func-
tion tests at diagnosis were within nor-
mal ranges in a considerable number of 
patients. Furthermore, the percentage 
of patients having the normal results of 
liver function tests was ranging from 
86.0% to 95.6%. Second, there were no 
patients who exhibited the significantly 
abnormal findings on hepatic imaging 
studies. Third, nonetheless, twenty-
nine patients with AAV exhibited sub-
clinical but significant liver fibrosis at 
diagnosis based on FIB-4. Fourth, pa-
tients with FFS ≥1 had a significantly 
higher risk of having subclinical but 
significant liver fibrosis (FIB-4 ≥1.45) 
than those with FFS <1 (RR 12.486). 
Thus, we conclude that AAV may influ-
ence on liver function and furthermore 
it may provoke subclinical but signifi-
cant liver fibrosis based on APRI and 
FIB-4, despite few abnormalities on 
imaging studies. 
A previous study reported that ALT and 
ALP were remarkably elevated in GPA 
patients compared to MPA and EGPA 
patients (6). In order to evaluate the 
effect of AAV variant on liver func-
tion, we compared the mean results of 
liver function tests among MPA, GPA 
and EGPA using One-Way-Anova test. 
However, we could find no significant 
differences in the mean level of those 
results among 3 AAV variants at all: 
PLT (323, 800 for MPA, 378,400 for 
GPA and 350,900 for EGPA, p=0.378); 
prothrombin time (INR) (1.0 for 
MPA, 1.0 for GPA and 1.0 for EGPA, 
p=0.730; ALP (84.0 for MPA, 129.8 
for GPA and 87.6 for EGPA, p=0.108); 
AST (22.2 for MPA, 22.3 for GPA and 
27.8 for EGPA, p=0.480); ALT (20.2 
for MPA, 30.5 for GPA and 26.8 for 
EGPA, p=0.447); total bilirubin (0.5 
for MPA, 0.6 for GPA and 0.6 for 
EGPA, p=0.576). Thus, we conclude 
that AAV variant may not affect liver 
function at diagnosis. 
In this study, we first applied APRI and 
FIB-4 to patients with AAV, particu-
larly before immunosuppressive drugs 
were administered. And we demon-
strated 21.3% of AAV patients had a 
potential of subclinical but significant 
liver fibrosis at diagnosis. The predic-
tive value of FIB-4 for liver fibrosis 
has been validated and the critical cut-
off of 1.45 for significant liver fibrosis 
has high specificity of 0.75 (24). On 
the other hands, in the present study, 
patients with FIB-4 ≥1.45 exhibited no 
clinically serious liver structural abnor-
malities on imaging studies. Therefore, 
our results may provide a lesson that 
subclinical but significant liver fibro-
sis might have been underestimated to 
date despite the performance of routine 
laboratory tests or imaging studies.
When we recognise liver fibrosis ≥S2 
by FIB-4 ≥1.45, we may consider the 
prompt performance of transient elas-
tography or liver biopsy. Here, we pro-
vide three reasons why we should cal-
culate FIB-4 in all patients with AAV at 
diagnosis as follows; i) if we recognise 
FIB-4 ≥1.45, perform transient elastog-
raphy or liver biopsy, and confirm that 
liver fibrosis is provoked by AAV (25), 
we should increase the doses of immu-
nosuppressive drugs or change them to 
others; ii) if we confirm that liver fibro-
sis is related to hepatotoxicity of im-
munosuppressive drugs administered, 
we should decrease the doses of those 
drugs or quit them, if possible; iii) if we 
confirm that liver fibrosis is provoked 
by incidental liver diseases such as pri-
mary sclerosing cholangitis or nodular 
regenerative hyperplasia which have 
reactivity to multiple autoantibodies 
including ANCAs (26), we should refer 
patients to Hepatologists. 
We demonstrated the association be-
tween FFS and FIB-4 at diagnosis of 
AAV. We do not calculate FIB-4 in all 
patients, but we usually assess FFS in 
almost all the patients at diagnosis. 
Therefore, we suggest a clinical and 
critical pathway for predicting sub-
Fig. 2. The association of BVAS or FFS with subclinical but significant liver fibrosis at diagnosis. 
Among 136 patients with AAV, 3 patients (2.2%) and 29 patients (21.3%) exhibited APRI ≥0.5 and 
FIB-4 ≥1.45, which suggest significant liver fibrosis. We compared both BVAS and FFS at diagnosis 
between patients with APRI ≥ 0.5 and those with APRI <0.5, but there were no significant differences 
between the two groups. We also compared both BVAS and FFS at diagnosis between patients with 
FIB-4 ≥1.45 and those with FIB-4 <1.45. The mean BVAS at diagnosis did not differ between the two 
groups. However, patients with FIB-4 ≥1.45 had the significantly higher mean FFS at diagnosis than 
those with FIB-4 <1.45. BVAS: Birmingham vasculitis activity score; FFS: five factor score; AAV: 
antineutrophil cytoplasmic antibody-associated vasculitis; APRI: the aspartate aminotransferase to 
platelet ratio index; FIB-4: an index of fibrosis. 
Fig. 3. The optimal cut-off of FFS in predicting 
FIB-4 ≥1.45. When we classified 136 patients 
with AAV into the two groups based on the cal-
culated cut-off of FFS at diagnosis, thirty-four 
patients were partitioned into the group with FFS 
at diagnosis ≥1. FIB-4 ≥1.45 was identified more 
frequently in these patients than in those with 
FFS <1. Furthermore, patients with FFS ≥1 had a 
significantly higher risk of having subclinical but 
significant liver fibrosis according to FIB-4 ≥1.45 
than those with FFS <1 (RR 12.486). FFS: five 
factor score; FIB-4: an index of fibrosis; AAV: 
antineutrophil cytoplasmic antibody-associated 
vasculitis; RR: relative risk. 
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clinical but significant liver fibrosis by 
hepatic manifestation of AAV at diag-
nosis. First, physicians should check 
whether FFS at diagnosis is more than 
1. Second, when FFS is more than 1, 
physicians should calculate FIB-4. 
Third, when FIB-4 is more than 1.45, 
physicians should consider non-inva-
sive liver stiffness measurement using 
transient elastography. Last, when sig-
nificant liver fibrosis (≥S2) is detected 
by transient elastography, physicians 
should refer patients to Hepatologists 
for liver biopsy.
Our study has several advantages: first, 
we first demonstrate that 21.3% of im-
munosuppressive drug-native patients 
with AAV had a potential of subclinical 
but significant liver fibrosis (≥S2) us-
ing FIB-4. Second, we provide a clini-
cal and critical pathway for predicting 
liver fibrosis in AAV patients at diagno-
sis. Third, we minimise the confound-
ing factors to exclude patients who had 
concomitant chronic liver diseases and 
autoimmune diseases and those who 
were exposed to immunosuppressive 
drugs.
Meanwhile, our study also has several 
issues: first, because the aim of this 
study was to investigate how many 
patients might exhibit subclinical but 
significant liver fibrosis, we provided 
no histological information on liver 
in patients exhibiting the abnormal 
results of liver function tests, particu-
larly those having APRI ≥0.5 or FIB-
4 ≥1.45. Second, due to the limitation 
of a retrospective study, we could not 
collect the result of gamma-glutamyl 
transferase, which is one of important 
enzymes to represent liver function. 
Third, our study was a cross-sectional 
study, so we could not clarify whether 
subclinical liver involvement of AAV 
may be associated with the frequency 
and severity of adverse events and drug 
toxicities during the follow-up. We be-
lieve that future prospective studies 
with the histological results and the 
serial laboratory and imaging data on 
liver including gamma-glutamyl trans-
ferase and FIB-4 in AAV patients with 
FIB-4 ≥1.45 will overcome these is-
sues of our pilot study. 
In conclusion, AAV may increase the 
results of liver function tests and it 
may provoke subclinical but significant 
liver fibrosis at diagnosis. Furthermore, 
liver fibrosis should be considered in 
AAV patients having FFS ≥1. 
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